CCL3 and malaria: Based on the current findings that show no differences in MIP-1α or MIP-1β levels between severe complications, MIP-1α and MIP-1β levels may not be specific to severe malaria or may not be specific markers of severe malaria complications, possibly due to differentially enhanced humoral and cellular immune responses [56].